Advertisement
Research Article| Volume 42, ISSUE 12, P1807-1816, August 2006

Prognostic factors for progression of childhood optic pathway glioma: A systematic review

      Abstract

      A systematic literature review was carried out to evaluate best existing evidence on prognostic factors for progression of childhood optic pathway glioma. Databases were searched for relevant articles and articles selected independently by two authors. Information about study design, population, treatment, outcome and prognostic analysis were abstracted and the quality of each article was assessed. A total of 23 articles met the inclusion criteria. Many studies had important methodological limitations, regarding external and internal validity. Eleven studies evaluated possible prognostic factors in a multivariate analysis. Three high-quality studies indicated age < 1 year as an independent prognostic factor for a worse progression-free survival. Three studies with multivariate analysis, including one high-quality study, found that children with neurofibromatosis type 1 (NF-1) have a better progression-free survival than those without NF-1. Two studies with multivariate analysis found tumour site to be a prognostic factor, both with some methodological limitations. In conclusion, this systematic review demonstrates that only a few of the prognostic factors proposed have been proven to be clinically relevant. Age < 1 year is a clear and independent prognostic factor for progression-free survival. Other prognostic factors, such as NF-1, tumour site and others, are suggested, but are still without solid evidence and need further high-quality studies to be clearly proven.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Listernick R.
        • Louis D.N.
        • Packer R.J.
        • Gutmann D.H.
        Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.
        Ann Neurol. 1997; 41: 143-149
        • Parsa C.F.
        • Hoyt C.S.
        • Lesser R.L.
        • et al.
        Spontaneous regression of optic gliomas: thirteen cases documented by serial neuroimaging.
        Arch Ophthalmol. 2001; 119: 516-529
        • Laupacis A.
        • Wells G.
        • Richardson W.S.
        • et al.
        Users’ guides to the medical literature. V. How to use an article about prognosis. Evidence-based medicine working group.
        JAMA. 1994; 272: 234-237
        • Altman D.G.
        Systematic reviews of evaluations of prognostic variables.
        BMJ. 2001; 323: 224-228
        • Van der Pal H.J.
        • van Dalen E.C.
        • Kremer L.C.M.
        • Bakker P.J.
        • van Leeuwen F.E.
        Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review.
        Cancer Treat Rev. 2005; 31: 173-185
        • Kovalic J.J.
        • Grigsby P.W.
        • Shepard M.J.
        • Fineberg B.B.
        • Thomas P.R.
        Radiation therapy for gliomas of the optic nerve and chiasm.
        Int J Radiat Oncol Biol Phys. 1990; 18: 927-932
        • Jenkin D.
        • Angyalfi S.
        • Becker L.
        • et al.
        Optic glioma in children: surveillance, resection, or irradiation?.
        Int J Radiat Oncol Biol Phys. 1993; 25: 215-225
        • Deliganis A.V.
        • Geyer J.R.
        • Berger M.S.
        Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma.
        Neurosurgery. 1996; 38 (discussion 1118–9): 1114-1118
        • Janss A.J.
        • Grundy R.
        • Cnaan A.
        • et al.
        Optic pathway and hypothalamic/chiasmatic gliomas in children younger than age 5 years with a 6-year follow-up.
        Cancer. 1995; 75: 1051-1059
        • Regueiro C.A.
        • Ruiz M.V.
        • Millan I.
        • de la Torre A.
        • Romero J.
        • Aragon G.
        Prognostic factors and results of radiation therapy in optic pathway tumors.
        Tumori. 1996; 82: 353-359
        • Erkal H.S.
        • Serin M.
        • Cakmak A.
        Management of optic pathway and chiasmatic-hypothalamic gliomas in children with radiation therapy.
        Radiother Oncol. 1997; 45: 11-15
        • Prados M.D.
        • Edwards S.B.M.
        • Lamborn K.
        • Davisand V.
        • Levin A.
        Treatment of pediatric low-grade gliomas with nitrosurea-based multiagent chemotherapy regimen.
        J Neuro-Oncol. 1997; 32: 235-241
        • Packer R.J.
        • Ater J.
        • Allen J.
        • et al.
        Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.
        J Neurosurg. 1997; 86: 747-754
        • Chan M.Y.
        • Foong A.P.
        • Heisey D.M.
        • Harkness W.
        • Hayward R.
        • Michalski A.
        Potential prognostic factors of relapse-free survival in childhood optic pathway glioma: a multivariate analysis.
        Pediatr Neurosurg. 1998; 29: 23-28
        • Schroder S.
        • Baumann-Schroder U.
        • Hazim W.
        • Haase W.
        • Mautner V.F.
        Long-term outcome of gliomas of the visual pathway in type 1 neurofibromatosis.
        Klin Monatsbl Augenheilkd. 1999; 215: 349-354
        • Grill J.
        • Laithier V.
        • Rodriguez D.
        • Raquin M.A.
        • Pierre-Kahn A.
        • Kalifa C.
        When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre.
        Eur J Pediatr. 2000; 159: 692-696
        • Grabenbauer G.G.
        • Schuchardt U.
        • Buchfelder M.
        • et al.
        Radiation therapy of optico-hypothalamic gliomas (OHG)-radiographic response,vision and late toxicity.
        Radiother Oncol. 2000; 54: 239-245
        • Kornreich L.
        • Blaser S.
        • Schwarz M.
        • et al.
        Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis.
        AJNR Am J Neuroradiol. 2001; 22: 1963-1969
        • Gayre G.S.
        • Scott I.U.
        • Feuer W.
        • Saunders T.G.
        • Siatkowski R.M.
        Long-term visual outcome in patients with anterior visual pathway gliomas.
        J Neuroophthalmol. 2001; 21: 1-7
        • Balcer L.J.
        • Liu G.T.
        • Heller G.
        • et al.
        Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas relation to tumor location by magnetic resonance imaging.
        Am J Ophthalmol. 2001; 131: 442-445
        • Massimino M.
        • Spreafico F.
        • Cefalo G.
        • et al.
        High response rate to cisplatin/etoposide regimen in childhood low-grade glioma.
        J Clin Oncol. 2002; 20: 4209-4216
        • Gururangan S.
        • Cavazos C.
        • Ashley D.
        • et al.
        Phase II study of Carboplatin in children with progressive low-grade gliomas.
        J Clin Oncol. 2002; 13: 2951-2958
        • Khafaga Y.
        • Hassounah M.
        • Kandil A.
        • et al.
        Optic gliomas: a retrospective analysis of 50 cases.
        Int J Radiat Oncol Biol Phys. 2003; 56: 807-812
        • Fouladi M.
        • Wallace D.
        • Langston J.W.
        • et al.
        Survival and functional outcome of children with hypothalamic/chiasmatic tumors.
        Cancer. 2003; 97: 1084-1092
        • Laithier V.
        • Grill J.
        • Le Deley M.C.
        • et al.
        Progression-free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy-results of the first French prospective study for the French Society of Pediatric Oncology.
        J Clin Oncol. 2003; 21: 4572-4578
        • Gnekow A.K.
        • Kortmann R.D.
        • Pietsch T.
        • Emser A.
        Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy – report from the multicenter treatment study for children and adolescents with a low grade glioma – HIT-LGG 1996 – of the Society of Pediatric Oncology and Hematology (GPOH).
        Klin Padiatr. 2004; 216: 331-342
        • Komotar R.J.
        • Burger P.C.
        • Carson B.S.
        • et al.
        Pilocytic and Pilomyxoid Hypothalamic/Chiasmatic Astrocytomas.
        J Neurosurg. 2004; 72: 72-80
      1. Perilongo G, Gnekow A, Kortmann R, et al. Treatment results of the first cooperative chemotherapy trial run by the International Research Consortium on Childhood Low Grade Glioma – LGG93 – a study of the Brain Tumor Sub-Committee of the International Society of Pediatric Oncology (SIOP). Eur J Cancer 2006, (in press).